Michael Wang, MD

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center

N/A

Poster(s):

• 2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.